All News

In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly integrated healthcare solutions, questions emerge around U.S. funding tied to global vaccine policy shifts, and the FDA approves a new treatment option for adults with presbyopia.

The guidance provides clarity to drug manufacturers on offering lower drug prices directly to patients, including patients on Medicare and Medicaid.

Public Citizen’s lawsuit highlights broader concerns over government transparency and oversight in pharmaceutical policy.

Tenpoint Therapeutics has paired FDA's approval for Yuvezzi with $235 million in new financing to support its U.S. launch and broader push into age-related vision loss.

In the final part of his conversation with Pharmaceutical Executive, Clay Siegall (president and CEO of Immunome) details the next steps for his upcoming medication.

The preservative, which contains a form of Mercury, has long been the target of anti-vaccine groups, despite studies demonstrating its safety.

EVERSANA president Greg Skalicky continues the conversation, providing details about the commercialization strategy.

As precision medicine shifts from promise to practice, true patient impact will depend less on standalone drugs and more on whether pharma, MedTech, and diagnostics can finally converge to build integrated systems of care.

In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a billion-dollar research partnership targeting hearing loss, and industry leaders examine what it takes to bring breakthrough rare disease products to patients.

The collaboration with Qilu extends Insilico’s application of generative AI into cardiometabolic disease drug discovery, with both companies aiming to advance candidates from early design through development under a shared strategic framework.

The FDA's approval is based on results from the Phase III CEPHEUS study, showing deeper and more durable responses compared with standard therapy.

Immunome president and CEO Clay Siegall explains why the weeks following JP Morgan are just as important as the conference itself.

Precigen's president and CEO discusses the recent launch of Papzimeos.

Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management through real-world evidence, and differentiation as ADC pipelines become increasingly crowded.

In today’s Pharmaceutical Executive Daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, procurement leaders reassess compliance risks tied to unmanaged tail spend, and Boehringer Ingelheim enters a $1 billion collaboration with Simcere to advance bispecific antibody research.

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

Taking a more strategic, data-driven approach to tail spend can transform procurement from a fragmented cost center into a source of compliance strength, operational efficiency, and greater supply chain confidence.

The collaboration agreement strengthens Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.

Clay Siegall, president and CEO of Immunome, discusses what he saw investors getting excited for at the annual healthcare conference.

In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry experts examine why data visualization remains a weak point in biotech decision-making, and pediatricians weigh in on evolving vaccine guidance amid ongoing debate.

Both the AAP and CDC released their respective childhood vaccine guidance’s, including different vaccine administration recommendations, age limits, and combined vaccines.

Poor visualization techniques can oversimplify reality and make data less potent.

Mirum Pharmaceuticals’ acquisition of Bluejay Therapeutics adds brelovitug to its pipeline, positioning the company for a potential first approved treatment for chronic hepatitis delta virus while reinforcing its focus on late-stage rare liver disease development.

In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing activity, workforce burnout threatens the stability of the blood supply, and industry leaders assess whether artificial intelligence in pharma is reaching a critical inflection point.

Global pharmaceutical production surged in 2025 due to tariff-driven front-loading but is expected to slow as trade uncertainty, patent expirations, pricing pressure, and shifting industrial policy reshape the industry’s growth, investment, and supply chain strategies.

Persistent blood shortages compounded by widespread laboratory staffing burnout and vacancies are straining transfusion medicine, making investment in lab workforces critical to safeguarding patient access to lifesaving blood supplies.

In today’s Pharmaceutical Executive Daily, the World Health Organization finalizes the United States’ withdrawal from the global health body, Bristol Myers Squibb enters an $850 million collaboration with Janux Therapeutics to advance tumor-activated cancer therapies, and industry leaders examine how real-world data is increasingly shaping patient access decisions.

The decision is based on President Trump’s executive order issued last year.